hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== See also == List of Disney theatrical animated feature films Walt Disney Home Video (VHS) List of Disney feature-length home entertainment releases List of Disney Channel original films Walt Disney Records discography List of Disney television series Lists of Walt Disney Studios films Timeline of the Walt Disney Company List of programs broadcast by Disney Channel
=== European Union === In the European Union, semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes. Semaglutide (as Wegovy) is further indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with obesity (initial BMI ≥ 30 kg/m2) or who are overweight (initial BMI ≥ 27 kg/m2) and have at least one weight-related comorbidity such as dysglycemia (prediabetes or type 2 diabetes), hypertension, dyslipidemia, or cardiovascular disease. It is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents (aged twelve years and older) with obesity and body weight above 60 kg (130 lb). Semaglutide (as Kayshild) is indicated in conjunction with diet and exercise for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced liver fibrosis (stage F2 or F3).
The continuous and discrete spectra of physical systems can be modeled in functional analysis as different parts in the decomposition of the spectrum of a linear operator acting on a function space, such as the Hamiltonian operator. The classical example of a discrete spectrum (for which the term was first used) is the characteristic set of discrete spectral lines seen in the emission spectrum and absorption spectrum of isolated atoms of a chemical element, which only absorb and emit light at particular wavelengths. The technique of spectroscopy is based on this phenomenon. Discrete spectra are seen in many other phenomena, such as vibrating strings, microwaves in a metal cavity, sound waves in a pulsating star, and resonances in high-energy particle physics. The general phenomenon of discrete spectra in physical systems can be mathematically modeled with tools of functional analysis, specifically by the decomposition of the spectrum of a linear operator acting on a functional space.
=== 21st century === As of 2014, there were more than 11,000 of these institutions worldwide. Many of the more established think tanks, created during the Cold War, are focused on international affairs, security studies, and foreign policy. The median think tank publishes 138 articles a year, albeit there is substantial variation, with the Brookings Institution having published 3,880 reports in 2020 alone. Other prolific publishers include the Wilson Center or the CSIS.
Sources: en.wikipedia.org
On 16 January 2015, the company announced that they would acquire Trophos for €470 million ($543 million) in order to increase the company's neuromuscular disease presence. The deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622). In April 2015, Roche acquired CAPP Medical, and its chief development of technology for cancer screening and monitoring via the detection of circulating tumour DNA. In August, the company announced its intention to acquire GeneWEAVE, Inc. for up to $425 million in order to strengthen its microbial diagnostics business. Days later the company acquired Kapa Biosystems, Inc. for $445M, focussing on next generation sequencing and polymerase chain reaction applications. In October 2015, the company acquired Adheron Therapeutics for $105 million (plus up to $475 million in milestone payments). In January 2016, the company announced it would acquire Tensha Therapeutics for $115 million upfront, with $420 million in contingent payments. In January 2017, the company acquired ForSight VISION4. In June, the company acquired the diabetes management platform, mySugr GmbH for an undisclosed price. In November Roche acquired Viewics, Inc. In late December the company announced it would acquire Ignyta Inc, expanding its global oncology business. In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion. In June of the same year the company announced it would acquire the outstanding shares of Foundation Medicine for $2.4 billion ($137 per share).
== Discovery and background == Phalloidin was one of the first cyclic peptides to be discovered. It was isolated from the death cap mushroom and crystallized by Feodor Lynen and Ulrich Wieland in 1937. Its structure is unusual in that it contains a cysteine-tryptophan linkage to form a bicyclic heptapeptide. This linkage had not been characterized before and makes the structure elucidation of phalloidin significantly more difficult. They determined the presence of the sulfur atom using UV spectroscopy and found that this ring structure had a slightly shifted wavelength. Raney nickel experiments confirmed the presence of sulfur in the tryptophan ring. The researchers found the desulfurized phalloidin was still circular, which demonstrated that the structure of phalloidin is normally bicyclic. Once linearized, the amino acid sequence of de-sulfurized phalloidin was elucidated through Edman degradation by Wieland and Schön in 1955. Due to its high affinity for actin, scientists discovered its potential use as a staining reagent for effective visualization of actin in microscopy. Derivatives conjugated with fluorophores are sold widely. Because of its ability to selectively bind filamentous actin (F-actin) and not actin monomers (G-actin), fluorescently labeled phalloidin is more effective than antibodies against actin.
=== Glycoprotein VI (GPVI) === Glycoprotein VI is one of the immunoglobulin superfamily type I transmembrane glycoproteins. It is an important collagen receptor involved in collagen-induced platelet activation and adhesion. It plays a key role in their procoagulant activity and subsequent thrombin and fibrin formation. Its procoagulant function may contribute to arterial or venous thrombosis. The FCR pathway of GPVI activation involves γ chain (GPVI transmembrane domain associates with γ chain FCR), Src kinase FYN / LYN, and LAT adaptor protein, all participating in phospholipase C activation.
=== Liver injury === A rare but serious side effect of venlafaxine is liver injury. It appears to affect both male and female patients with a median age of 44. Cessation of venlafaxine is one of the appropriate measures of management. While the mechanism of venlafaxine-related liver injury remains unclear, findings suggest that it may be related to a CYP2D6 polymorphism.
The brown population (officially called pardo in Portuguese) is a broad category that includes caboclos (assimilated Amerindians in general, and descendants of Whites and Natives), mulatos (descendants of primarily Whites and Afro-Brazilians) and cafuzos (descendants of Afro-Brazilians and Natives). Higher percents of Blacks, mulattoes and tri-racials can be found in the eastern coast of the Northeastern region from Bahia to Paraíba and also in northern Maranhão, southern Minas Gerais and eastern Rio de Janeiro. People of considerable Amerindian ancestry form the majority of the population in the Northern, Northeastern and Center-Western regions. In 2007, the National Indian Foundation estimated that Brazil has 67 different uncontacted tribes, up from their estimate of 40 in 2005. Brazil is believed to have the largest number of uncontacted peoples in the world.
Sources: en.wikipedia.org
. R is the gas constant and T is the absolute temperature. Note that pKa = −log(Ka) and 2.303 ≈ ln(10). At 25 °C, ΔG⊖ in kJ·mol−1 ≈ 5.708 pKa (1 kJ·mol−1 = 1000 joules per mole). Free energy is made up of an enthalpy term and an entropy term.
In May 2021, Freddy's hired Chris Dull as CEO to take over the top post from co-founder Randy Simon. In August 2022, Freddy's hired Brian Wise as COO to take over the operations post from co-founder Scott Redler. In November 2022, the company signed a master franchise and development agreement that will allow the brand to expand into Canada by 2025, opening restaurants in nine provinces. In August 2025, Rhône Group agreed to acquire Freddy's from Thompson Street Capital Partners, who acquired the brand in 2021, for an enterprise value of around $700 million. The acquisition was finalized in September 2025.
=== Immunology and neurobiology === Hood also made generative discoveries in the field of molecular immunology. His studies of the amino acid sequences of immunoglobulins (also known as antibodies) helped to fuel the 1970s' debate regarding the generation of immune diversity and supported the hypothesis advanced by William J. Dreyer that immunoglobulin (antibody) chains are encoded by two separate genes (a constant and a variable gene). He (and others) conducted pioneering studies on the structure and diversity of the antibody genes. This research led to verification of the "two genes, one polypeptide" hypothesis and insights into the mechanisms responsible for the diversification of the immunoglobulin variable genes. Hood shared the Lasker Award in 1987 for these studies. Additionally, Hood was among the first to study, at the gene level, the MHC (major histocompatibility complex) gene family and the T-cell receptor gene families as well as being among first to demonstrate that alternative RNA splicing was a fundamental mechanism for generating alternative forms of antibodies. He showed that RNA splicing is the mechanism for generating the membrane bound and the secreted forms of antibodies. In neurobiology, Hood and his colleagues were the first to clone and study the myelin basic protein (MBP) gene. The MBP is a central component in the sheath that wraps and protects neurons. Hood demonstrated that the condition called "shiverer mouse" arose from a defect in the MBP gene.
=== Occurrence in bacteria === Hydrogen cyanide is produced by various soil bacteria, including cyanobacteria and representatives of the genera Aeromonas, Bacillus, and Pseudomonas. Biosynthesis proceeds from glycine. A group of alkanenitriles was isolated from Pseudomonas veronii: dodecannitrile, tridecannitrile, tetradecanenitrile, pentadecannitrile, and hexadecannitrile, as well as compounds of similar chain length containing a double bond. From Micromonospora echinospora, structurally related compounds were also isolated, differing by a terminal methyl branch, a double bond, or both. A cyanohydrin containing a phosphonic acid moiety is known from Streptomyces regensis. The aetokthonotoxin from the cyanobacteria Aetokthonos hydrillicola is a brominated indole derivative bearing a nitrile group. It is a potent neurotoxin that frequently causes mortality in bald eagles that ingest it.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.